HOme Administration of Monoclonal antibodies: an Evaluation by Severe asthma patients

Home administration of monoclonal antibodies for severe asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON27883

Enrollment

100

Registered

2019-06-17

Start date

2019-06-17

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe asthma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria - >18 yr - Valid criteria for starting treatment with biologicals for severe asthma, according to international guidelines (ERS/ATS) - Home treatment will only be started when a positive response to therapy is found, during the first evaluation after four months

Exclusion criteria

Exclusion criteria: No

Design outcomes

Primary

Measure	Time frame
Patient satisfaction	—

Secondary

Measure	Time frame
- Safety of home treatment - Adherence to treatment with biologicals during self administration - ACQ, AQLQ/EQ5D5L and Health care utilisation - Cost-effectiveness - Motivation and selfmanagement behaviour (PAM)	—

Contacts

Public ContactSaar Van Nederveen-Bendien

HAGA Ziekenhuis

s.vannederveen@hagaziekenhuis.nl0031639592319

Outcome results